CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that ...

both CRISPR-based medicines. One of them is Lonvo-z, being developed to treat hereditary angioedema (HAE), a genetic disease ...

Groups of districts already working on escaping the factory model applied for grant money to work on innovative high school options.

According to Bloomberg News, Vinay Prasad, who oversees gene therapies at the FDA, said the plans will be published in early November. He foresees the approach sparking curiosity for the next wave of ...

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a natural defense system in bacteria that scientists have adapted into a powerful gene-editing tool. This ...

Vertex Pharmaceuticals (VRTX) is rapidly closing the market capitalization gap with pharmaceutical behemoth Pfizer (PFE), leveraging a robust growth trajectory and a diversified pipeline that ...